CSPC Pharmaceutical Group (CSPCY) Insider Trading & Ownership C$2.64 -0.10 (-3.65%) (As of 11/1/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisChartDividendInsider TradesShort Interest There is no recent insider trading on record for CSPC Pharmaceutical Group, but the stock has been recently traded by U.S. Congress members, who may have more information about the industry than the general public. Get CSPCY Insider Trade Alerts Want to know when executives and insiders are buying or selling CSPC Pharmaceutical Group stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Ad Chaikin AnalyticsSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.Now he's just issued a warning for the most popular stock in the world: Nvidia (NVDA). CSPC Pharmaceutical Group Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellAverage Share PriceTotal Transaction9/15/2023Josh GottheimerU.S. Congress Member (D-NJ)Sell$2.94$1,001 - $15,0007/14/2023Josh GottheimerU.S. Congress Member (D-NJ)Buy$3.20$1,001 - $15,0006/13/2023Josh GottheimerU.S. Congress Member (D-NJ)Sell$3.34$1,001 - $15,00012/30/2022Josh GottheimerU.S. Congress Member (D-NJ)Sell$4.08$1,001 - $15,0004/19/2022Josh GottheimerU.S. Congress Member (D-NJ)Buy$1,001 - $15,0003/15/2022Josh GottheimerU.S. Congress Member (D-NJ)Sell$1,001 - $15,0001/10/2022Josh GottheimerU.S. Congress Member (D-NJ)Buy$1,001 - $15,00012/9/2021Josh GottheimerU.S. Congress Member (D-NJ)Sell$1,001 - $15,000 (Data available from 1/1/2013 forward) CSPC Pharmaceutical Group Key ExecutivesMr. Dongchen Cai (Age 70)Executive Chairman Compensation: $2.61MMr. Cuilong Zhang (Age 55)Vice-Chairman & CEO Compensation: $1.39MMr. Chunlei Li (Age 48)Executive Director & Chief Scientist Compensation: $943.49kMr. Kin Man Chak (Age 58)Executive Director Compensation: $690.29kMr. Weidong Pan (Age 55)Executive Director Compensation: $501.46kMr. Huaiyu Wang (Age 61)Executive Director Compensation: $616.37kMr. Zhenguo Wang (Age 54)Executive Director Compensation: $499.06kDr. Qingxi Wang Ph.D. (Age 58)Executive Director Compensation: $435.55kDr. Hao Jiang (Age 40)Executive Director Compensation: $374.86kMr. Tai On Lo CPA (Age 70)Company Secretary More Insider Trading Tools from MarketBeat Related Companies Roche Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Big Buybacks Announced: 3 Stocks Insiders Are Banking OnInsiders Are Buying High-Yielding Delek Logistics PartnersInsider Selling is not a Signal to Start Selling Gartner Stock2 Stocks to Buy and 1 to Sell - Smart Moves for Investors3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside This page (OTCMKTS:CSPCY) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | SponsoredWall St. Legend: Millions of Americans About to Fall Out of the 1%Wall Street insider reveals the financial tidal wave about to knock millions of Americans out of the One Perce...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CSPC Pharmaceutical Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share CSPC Pharmaceutical Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
